Start Submission Become a Reviewer

Reading: Current Status of Malaria and Anti-Malarial Drug Resistance in Sri Lanka


A- A+
Alt. Display

Research Articles

Current Status of Malaria and Anti-Malarial Drug Resistance in Sri Lanka


Rupika S Rajakaruna ,

Department of Zoology, University of Peradeniya, Peradeniya, Sri Lanka, LK
X close

Priyanie H Amerasinghe,

IWMI, C/O ICRISAT, Patancheru - 502 324, Hyderabad, Andhra Pradesh, India, IN
X close

Gawrie NL Galappaththy,

Anti-Malarial Campaign Head Office, Colombo, Sri Lanka, LK
X close

Flemming Konradsen,

Centre for Medical Parasitology, Institute of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark, DK
X close

Olivier JT Briet

International Water Management Institute (IWMI), P.O. Box 2075, Colombo, Sri Lanka, LK
X close


Even though malaria continues to cause high morbidity and mortality in most of the malaria endemic countries in the world, it is currently not a major health problem in Sri Lanka. Despite the low malaria incidence, the development and spread of anti-malarial drug resistance, combined with a recent increase in the armed conflict hindering provision of effective health services will make it difficult to control malaria in Sri Lanka. Since chloroquine (CQ) resistant Plasmodium falciparum was first reported from Dambulla area in 1984, the number has increased to more than 50% observed in vivo from various endemic areas. In concordance with this, single nucleotide polymorphisms (SNPs) in genes of P. falciparum responsible for CQ resistance are present. A limited number of trials have investigated the efficacy of the second line drug, sulfadoxine/ pyrimethamine (SP) against P. falciparum and a few cases of resistance have been reported. Moreover, SNPs in P. falciparum genes responsible for SP resistance are present and may constitute a sign of evolving SP resistance development. For P. vivax, drug resistance is not yet recorded as a problem in Sri Lanka, however the prevalence of SP resistant SNPs in P. vivax populations seems high and may pose a risk despite that SP is not used directly against P. vivax infections. Continuous monitoring of drug efficacy in vivo, as well by measuring the prevalence of SNPs related to drug resistance are major issues to be addressed.

doi: 10.4038/cjsbs.v37i1.493

Cey. J. Sci. (Bio. Sci.) 37 (1): 15-22, 2008

How to Cite: Rajakaruna, R.S., Amerasinghe, P.H., Galappaththy, G.N., Konradsen, F. and Briet, O.J., 2009. Current Status of Malaria and Anti-Malarial Drug Resistance in Sri Lanka. Ceylon Journal of Science (Biological Sciences), 37(1), pp.15–22. DOI:
Published on 16 Jun 2009.
Peer Reviewed


  • PDF (EN)

    comments powered by Disqus